Long-Term Structural Outcomes of Late-Stage RPE65 Gene Therapy

Abstract excerpt

The form of hereditary childhood blindness Leber congenital amaurosis (LCA) caused by biallelic RPE65 mutations is considered treatable with a gene therapy product approved in the US and Europe. The resulting vision improvement is well accepted, but long-term outcomes on the natural history of retinal degeneration are controversial. We treated four RPE65-mutant dogs in mid-life (age = 5-6 years) and followed them...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Ocular Disorders and Treatments
• Share to Retinal Development and Disorders
• Share to Retinal Diseases and Treatments